These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9454284)
1. [Adjuvant treatment after radical prostatectomy in prostatic carcinoma (pT3 or pTxN+): prognostic factors and results]. Zincke H Praxis (Bern 1994); 1997 Nov; 86(46):1825-32. PubMed ID: 9454284 [TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE; Blute ML; Zincke H Semin Urol Oncol; 1996 May; 14(2 Suppl 2):12-20; discussion 21. PubMed ID: 8725887 [TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287 [TBL] [Abstract][Full Text] [Related]
5. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Hawkins CA; Bergstralh EJ; Lieber MM; Zincke H Urology; 1995 Sep; 46(3):356-64. PubMed ID: 7544934 [TBL] [Abstract][Full Text] [Related]
6. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. Zincke H; Lau W; Bergstralh E; Blute ML J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737 [TBL] [Abstract][Full Text] [Related]
7. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
8. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701 [TBL] [Abstract][Full Text] [Related]
9. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432 [TBL] [Abstract][Full Text] [Related]
10. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy. Wu TT; Wang JS; Lu CM; Lee YH; Huang JK Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related]
12. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984 [TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for clinical T4 prostate cancer. Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
15. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
17. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Freedland SJ; Partin AW; Epstein JI; Walsh PC Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852 [TBL] [Abstract][Full Text] [Related]
18. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy. Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491 [TBL] [Abstract][Full Text] [Related]
19. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
20. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]